LUGPA 2026 Global Prostate Cancer Congress Enduring Program-Session 1

Video Transcription

Video Summary

The meeting chair opens by emphasizing that the program spans the full prostate cancer continuum—from screening and biomarkers through advanced imaging and theranostics—arguing clinicians can’t practice as they did five years ago. The agenda aims to bridge clinical trial data with “real-world” outcomes, with attention to ADT toxicity, supportive care, and cross-specialty collaboration. The first session begins with integrative cancer care.<br /><br />Dr. Michael Wyss presents practical lifestyle guidance for men with elevated PSA or on active surveillance: reduce Western/high-fat dietary patterns in favor of Mediterranean-style eating, prioritize meaningful exercise (about three hours/week at a brisk pace), minimize alcohol, and stop smoking. He discusses how healthy lifestyle changes may particularly reduce lethal prostate cancer risk in men with high polygenic genetic risk. He cautions against supplements, citing SELECT data suggesting vitamin E may increase prostate cancer risk. Wyss then highlights the gut microbiome as a modifiable factor influencing immunity and metabolite production, potentially linking gut health to prostate cancer risk and progression. He describes emerging approaches: microbiome-based risk scoring from stool, personalized nutrition, engineered probiotics, suppressing harmful bacteria, and metabolite manipulation.<br /><br />An advanced practice provider (APP) leader outlines how NP/PA-directed urology clinics expand access amid urologist shortages, deliver protocol-driven care, perform increasing numbers of procedures, coordinate multidisciplinary GU cancer survivorship, and can be financially beneficial.<br /><br />Dr. William Parker reviews testosterone replacement therapy (TRT) in prostate cancer, noting limited evidence but growing support: observational data suggest TRT may be reasonable during active surveillance, appears safe after curative treatment (especially post-prostatectomy with undetectable PSA), and may help men with persistent hypogonadism after ADT.<br /><br />A UCSD PA reviews caregiver burden: caregiving is rising (63 million caregivers in 2025), often financially and emotionally taxing, complicated by multi-specialist care and digital communication. She urges clinicians to acknowledge caregivers, clarify expectations, and connect them with resources.<br /><br />The session concludes with a physician–patient story: a long-term metastatic CRPC survivor with durable undetectable PSA who later restarted testosterone, reporting major improvements in mood, libido, cognition, and activity, illustrating quality-of-life stakes and individualized care.

Keywords

prostate cancer continuum

active surveillance lifestyle

Mediterranean diet

exercise recommendations

polygenic risk score

vitamin E SELECT trial

gut microbiome modulation

microbiome-based risk scoring

advanced practice provider urology clinics

testosterone replacement therapy after prostate cancer

caregiver burden and support resources